About Taiho Ventures

The corporate venture arm of Taiho Pharma.

Our mission is to create significant value by investing in the global biotech venture community — and to bring new science to Taiho Pharmaceutical Co., Ltd.

Our story

Ten years of conviction, in six chapters.

012016

Founded in Menlo Park

Taiho Pharmaceutical establishes its corporate venture arm at 2420 Sand Hill Road. Its first investment goes to Arcus Biosciences.

022017

The Arcus partnership

An option and license agreement gives Taiho exclusive rights, in certain Asian territories, to five Arcus programs.

032018

The fund triples to $300M

Taiho expands the fund from its initial $50M to $300M. Arcus completes its IPO on the NYSE (RCUS).

042019 — 2021

Four more companies go public

NextCure, Harpoon, ORIC, and Werewolf reach the public markets.

052024

A $400M fund, and a first exit

The fund grows to $400M. Merck acquires Harpoon Therapeutics, the portfolio's first acquisition.

062025 — 2026

Three more exits, a decade in

Sanofi acquires Dren Bio's lead asset and Johnson & Johnson acquires Halda for $3.05 billion in 2025; Eli Lilly's acquisition of Orna follows in 2026 — the firm's tenth year.

20162026

Our office

In the heart of Menlo Park

Based in Menlo Park, California, our team operates at the center of the venture community, connecting breakthrough innovation with Taiho Pharmaceutical's global network.

United States · Headquarters

Menlo Park, CA

Taiho Ventures, LLC
2420 Sand Hill Road, Suite 203
Menlo Park, CA 94025-6940

Get directions →